Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

Gamida Cell Ltd. (NASDAQ: GMDA) announced that CEO Abbey Jenkins will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 9:20 a.m. ET. The presentation will cover corporate highlights and updates on the lead product candidate, omidubicel, which has a PDUFA action date set for May 1, 2023, from the FDA. Omidubicel is an advanced cell therapy for allogeneic stem cell transplants, designed to improve outcomes for blood cancer patients. The candidate has shown a significant reduction in engraftment times and fewer complications compared to standard treatments. The webcast will be available on Gamida Cell's website for 14 days.

BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate highlights at the upcoming Oppenheimer 33^rd Annual Healthcare Conference on March 14^th, 2023 at 9:20 a.m. ET.

Ms. Jenkins will discuss company updates, including preparations for the potential approval of the lead product candidate, omidubicel, which has a target PDUFA action date with the U.S. Food and Drug Administration (FDA) of May 1, 2023.

The webcast will be available on the “Investors & Media” section of Gamida Cell’s website at www.gamida-cell.com, and will be available for at least 14 days following the event.

About Omidubicel

Omidubicel is an advanced cell therapy candidate for allogeneic hematopoietic stem cell (bone marrow) transplant that, if approved, has the potential to expand access and improve outcomes for patients with blood cancers. Omidubicel demonstrated a statistically significant reduction in time to neutrophil engraftment in comparison to standard umbilical cord blood in an international, multi-center, randomized Phase 3 study (NCT02730299) in patients with hematologic malignancies undergoing allogeneic bone marrow transplant. The Phase 3 study also showed reduced time to platelet engraftment, reduced infections and fewer days of hospitalization. One year post-transplant data showed sustained clinical benefits with omidubicel as demonstrated by significant reduction in infectious complications as well as reduced non-relapse mortality and no significant increase in relapse rates nor increases in graft-versus-host-disease (GvHD) rates. Omidubicel is the first stem cell transplant donor source to receive Breakthrough Therapy Designation from the FDA and has also received Orphan Drug Designation in the US and EU. Omidubicel has a PDUFA target action date of May 1, 2023.

Omidubicel is an investigational stem cell therapy candidate, and its safety and efficacy have not been established by the FDA or any other health authority. For more information about omidubicel, please visit https://www.gamida-cell.com.

About Gamida Cell

Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. The company has a diverse pipeline of potentially curative cell therapy candidates for patients with blood cancers and solid tumors. We apply a proprietary expansion platform leveraging the properties of NAM to allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create therapy candidates with the potential to redefine standards of care. These include omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant that, if approved, has the potential to expand access and improve outcomes for patients with blood cancers, and a line of enhanced and engineered NK cells targeted at solid tumors and hematological malignancies. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, Twitter, Facebook or Instagram at @GamidaCellTx.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to timing of the FDA’s review of the BLA for omidubicel, and the potentially life-saving or curative therapeutic and commercial potential of Gamida Cell’s product candidates (including omidubicel). Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on our business; clinical, scientific, regulatory and technical developments; and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (SEC) on November 14, 2022, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cell’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Gamida Cell’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell. As a result, you are cautioned not to rely on these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005599/en/

Investor Contact:

Courtney Turiano

Stern Investor Relations, Inc.

Courtney.Turiano@sternir.com

1-212-362-1200

Media Contact:

Dan Boyle

Orangefiery

dan@orangefiery.com

1-818-209-1692

Source: Gamida Cell Ltd.

FAQ

What is the purpose of Gamida Cell's presentation at the Oppenheimer Conference on March 14, 2023?

Gamida Cell's presentation will highlight corporate updates and discuss the lead product candidate, omidubicel.

What is the PDUFA action date for omidubicel and what does it signify?

The PDUFA action date for omidubicel is May 1, 2023, which indicates when the FDA will review the drug for potential approval.

How does omidubicel improve the outcomes for patients undergoing stem cell transplants?

Omidubicel has demonstrated a statistically significant reduction in engraftment times and fewer complications compared to standard umbilical cord blood treatments.

Where can investors access the webcast of Gamida Cell's presentation?

The webcast will be available in the 'Investors & Media' section of Gamida Cell's website for at least 14 days following the conference.

What are the main clinical benefits of omidubicel reported in the Phase 3 study?

Omidubicel showed reduced time to neutrophil and platelet engraftment, fewer infections, and decreased hospitalization days.